November / December 1998

Vol 5, No 6 CME Pretest

In this issue, the topic of prostate cancer is addressed. First, answer the pretest questions below. After reading the articles, proceed with answering the CME posttest questions.

This Journal provides 4 hours of Category 1 Continuing Medical Education

Complimentary CME Credits

Physicans can earn up to 4 credit hours of Category 1 for the Physican's Recognition Award of the American Medical Association by reading the material in this issue and successfully answering the questions on the posttest at the end of this issue. Complete instructions are given on the posttest pages. Every successfully answered 10 questions will earn 1 credit hour. CME is presented by an unrestricted educational grant from Bristol-Myers Oncology Division.

Educational Objectives

After reading this issue, clinicians will be expected to:

• understand current methods for diagnosing, imaging, and staging prostate cancer, and
  
• be familiar with new approaches for treating advanced prostate cancer.
  

This program was planned in accordance with ACCME Essentials.
Release Date: November 1, 1998 Expiration Date: November 1, 1999

Pretest

1. The number of new prostate cancer in the United States for 1998 is estimated to be:

a. 52,000

b. 112,000

c. 185,000

d. 215,000

2. The average duration of response of symptomatic patients with metastatic prostate cancer to androgen deprivation is:

a. 12 months

b. 15 months

c. 24 months

d. 36 months

3. Prostate cancer cell lines have what proportion of mutations in the p53 gene?

a. 30%

b. 60%

c. 70%

d. 90%